CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

CSL shares are back below $100 after a brutal sell-off. The post Under $100, are CSL shares finally too cheap to ignore? appeared first on The Motley Fool Australia.

Can this giant produce healthy returns or is there more downside to come? The post Here are the latest growth forecasts for ...

A leading fund manager forecasts a looming rebound for CSL shares. But why? The post 3 compelling reasons to buy CSL shares today appeared first on The Motley Fool Australia.

CSL reveals lower FY26 earnings guidance and significant asset impairments. The post CSL cuts FY26 guidance, flags $5bn in impairments appeared first on The Motley Fool Australia.

(RTTNews) - Australian biotech company CSL Ltd. (CSL.AX, CMXHF.PK) reported a net profit after tax of US$1.90 billion for the half year ended 31 December 2023, up 20% on a constant currency basis. On ...

Earnings call CSL reported H1 FY25 revenue of AUD 8.5B (+5% YoY, constant currency) and NPATA of AUD 2.1B (+5%), reaffirming FY25 NPATA guidance of AUD 3.2–3.3B (+10–13%). Behring led with 10% revenue ...

CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock ...

(Reuters) -Australian drugmaker CSL Ltd on Tuesday set the list price of its one-time gene therapy for hemophilia B at $3.5 million, making it the world's most expensive treatment, following its ...

Approaching the final week of November CSL Ltd ADR (OTCMKTS: CSLLY) received some good news as the United States Food and Drug Administration approved CSL Behring’s new gene therapy drug, HEMEGENIX ...

GSK Plc, Sanofi and CSL Ltd. secured $72 million from the United States government to ramp up production of bird flu vaccines ...